Highlights Zoetis Inc.

Equities

ZTS

US98978V1035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-01-16 pm EST			5-day change	1st Jan Change
124.65 ^USD	-0.50%		-1.73%	-0.93%

Jan. 12	Zoetis CEO on Animal Health, Vaccines and Beef Prices	MT
Jan. 12	Zoetis Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 10:30 AM

Highlights

Dec. 16	Zoetis Prices $1.75 Billion Convertible Notes Offering	MT
Dec. 15	Zoetis to Offer $1.75 Billion Convertible Notes Offering	MT
Dec. 15	Zoetis announces proposed $1.75 billion convertible senior notes offering	RE
Dec. 11	Zoetis Ups Quarterly Dividend to $0.53 per Share, Payable Mar. 3 to Holders of Record on Jan. 20	MT
Dec. 11	Zoetis declares first quarter 2026 dividend; board approves 6% payment increase	RE
Dec. 11	Zoetis Inc. Declares Dividend for the First Quarter of 2026, Payable on March 3, 2026	CI
Dec. 05	Zoetis Inc. Receives Health Canada Approval for Portela?? (Relfovetmab Injection) to Alleviate Pain Associated with Osteoarthritis in Cats	CI
Dec. 05	Zoetis receives Health Canada approval for Portela (Relfovetmab injection)	RE
Nov. 26	Zoetis receives European Commission marketing authorization for Lenivia (izenivetmab) to reduce pain associated with osteoarthritis (OA) in dogs	RE
Nov. 26	Zoetis Inc. Receives European Commission Marketing Authorization for Lenivia®? (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs	CI
Nov. 18	Traders Strap In, Again
Nov. 10	Zoetis Inc. acquired Veterinary Pathology Group Limited.	CI
Nov. 04	Tranche Update on Zoetis Inc.'s Equity Buyback Plan announced on August 1, 2024.	CI
Nov. 04	Zoetis trims annual revenue forecast on muted demand for animal treatments, shares slide	RE
Nov. 04	Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	MT
Nov. 04	Zoetis Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 04	Zoetis Inc. Maintains Earnings Guidance for 2025	CI
Nov. 04	(ZTS) Zoetis Expects Full Year 2025 Revenue Range $9.40B - $9.48B, vs. FactSet Est of $9.51B	MT
Nov. 04	Zoetis Q3 Adjusted Earnings, Revenue Rise; Annual Sales Outlook Revised -- Shares Down Pre-Bell	MT
Nov. 04	(ZTS) Zoetis Expects Full-Year 2025 Adjusted EPS Range $6.30 - $6.40, vs. FactSet Est of $6.35	MT
Nov. 04	Earnings Flash (ZTS) Zoetis Inc. Reports Q3 Revenue $2.40B, vs. FactSet Est of $2.41B	MT
Nov. 04	Earnings Flash (ZTS) Zoetis Inc. Posts Q3 Adjusted EPS $1.70 per Share, vs. FactSet Est of $1.62	MT
Nov. 04	Zoetis edges past Q3 revenue estimates, revises FY sales view	RE
25-10-29	Zoetis Inc. Receives European Commission Marketing Authorization for Portela (Relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats	CI
25-10-29	Zoetis receives European Commission marketing authorization for Portela® (Relfovetmab) to alleviate pain associated with osteoarthritis in cats	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Zoetis CEO on Animal Health, Vaccines and Beef Prices

January 12, 2026 at 05:26 pm EST

Zoetis returns to reasonable valuation multiples

September 25, 2025 at 04:23 am EDT